These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 8351755

  • 1. Platinum accumulation in the kidney and changes in creatinine clearance following chemotherapy with cisplatin in humans.
    Uozumi J, Ueda T, Yasumasu T, Koikawa Y, Naito S, Kumazawa J, Kamura T, Nakano H, Sueishi K.
    Urol Int; 1993; 51(2):57-61. PubMed ID: 8351755
    [Abstract] [Full Text] [Related]

  • 2. Platinum accumulation in the kidney and liver following chemotherapy with cisplatin in humans.
    Uozumi J, Ueda T, Yasumasu T, Koikawa Y, Naito S, Kumazawa J, Sueishi K.
    Int Urol Nephrol; 1993; 25(3):215-20. PubMed ID: 8225820
    [Abstract] [Full Text] [Related]

  • 3. Renal and hepatic concentrations of platinum: relationship to cisplatin time, dose, and nephrotoxicity.
    Stewart DJ, Mikhael NZ, Nanji AA, Nair RC, Kacew S, Howard K, Hirte W, Maroun JA.
    J Clin Oncol; 1985 Sep; 3(9):1251-6. PubMed ID: 4040958
    [Abstract] [Full Text] [Related]

  • 4. Renal handling of cis-diamminedichloroplatinum(II).
    Jacobs C, Kalman SM, Tretton M, Weiner MW.
    Cancer Treat Rep; 1980 Sep; 64(12):1223-6. PubMed ID: 7193518
    [Abstract] [Full Text] [Related]

  • 5. [Effects of combination chemotherapy with cis-diamminedichloroplatinum (II) (CDDP) on renal function in patients with urogenital malignancies].
    Kawamura J, Hida S, Higashi Y, Yamauchi T, Soeda A, Yoshida O.
    Hinyokika Kiyo; 1985 Feb; 31(2):207-21. PubMed ID: 4040315
    [Abstract] [Full Text] [Related]

  • 6. Time course of the binding of platinum to subfractions of the kidney cytosol in the cisplatin-treated rat.
    Mason R, Hogg S, Edwards IR.
    Res Commun Chem Pathol Pharmacol; 1986 Apr; 52(1):51-8. PubMed ID: 3715197
    [Abstract] [Full Text] [Related]

  • 7. Mechanism of cisplatin nephrotoxicity.
    Weiner MW, Jacobs C.
    Fed Proc; 1983 Oct; 42(13):2974-8. PubMed ID: 6684595
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin.
    Vermorken JB, van der Vijgh WJ, Klein I, Gall HE, van Groeningen CJ, Hart GA, Pinedo HM.
    Clin Pharmacol Ther; 1986 Feb; 39(2):136-44. PubMed ID: 3943271
    [Abstract] [Full Text] [Related]

  • 9. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity.
    Campbell AB, Kalman SM, Jacobs C.
    Cancer Treat Rep; 1983 Feb; 67(2):169-72. PubMed ID: 6681731
    [Abstract] [Full Text] [Related]

  • 10. Luteolin ameliorates cisplatin-induced nephrotoxicity in mice through inhibition of platinum accumulation, inflammation and apoptosis in the kidney.
    Domitrović R, Cvijanović O, Pugel EP, Zagorac GB, Mahmutefendić H, Škoda M.
    Toxicology; 2013 Aug 09; 310():115-23. PubMed ID: 23770416
    [Abstract] [Full Text] [Related]

  • 11. Serial-measured versus estimated creatinine clearance in patients with non-small cell lung cancer receiving cisplatin-based chemotherapy.
    Chang GC, Yang TY, Shih CM, Lin LY, Lee HS, Chiang CD.
    J Formos Med Assoc; 2003 Apr 09; 102(4):257-61. PubMed ID: 12833190
    [Abstract] [Full Text] [Related]

  • 12. Tissue platinum after clinical treatment with cisplatin or carboplatin in tumor-bearing patients.
    Minami T, Tohno Y, Tohno S, Utsumi M, Yamada M, Hashii K, Tateyama I, Kadota E, Okazaki Y.
    Biol Trace Elem Res; 1997 Apr 09; 58(1-2):77-83. PubMed ID: 9363322
    [Abstract] [Full Text] [Related]

  • 13. Increase in serum uric acid level associated with cisplatin therapy. Correlation with liver but not kidney platinum concentrations.
    Nanji AA, Mikhael NZ, Stewart DJ.
    Arch Intern Med; 1985 Nov 09; 145(11):2013-4. PubMed ID: 4062451
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
    Bonetti A, Apostoli P, Zaninelli M, Pavanel F, Colombatti M, Cetto GL, Franceschi T, Sperotto L, Leone R.
    Clin Cancer Res; 1996 Nov 09; 2(11):1829-35. PubMed ID: 9816137
    [Abstract] [Full Text] [Related]

  • 19. Validity of new methods to evaluate renal function in cancer patients treated with cisplatin.
    Funakoshi Y, Fujiwara Y, Kiyota N, Mukohara T, Shimada T, Toyoda M, Imamura Y, Chayahara N, Tomioka H, Umezu M, Otsuki N, Nibu K, Minami H.
    Cancer Chemother Pharmacol; 2016 Feb 09; 77(2):281-8. PubMed ID: 26791871
    [Abstract] [Full Text] [Related]

  • 20. Clinical pharmacokinetics of cumulative very high dose of cisplatin in chemotherapy resistant solid tumors.
    Tebano MT, Carlini P, Loizzo A, Luzi M, Petrucci F, Alimonti A, Caroli S.
    Ann Ist Super Sanita; 1995 Feb 09; 31(3):351-7. PubMed ID: 8712579
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.